Abstract
Pharmacy scope of practice and access to Opioid Agonist Therapies (OAT) in Canada after COVID-19 Sarah Lussier-Hoskyn, MA Economics, BPHA, affiliated scholar Canadian Health Policy Institute Brett Skinner, PhD, CEO Canadian Health Policy Institute, Editor Canadian Health
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
